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radiotherapy. Compared to the group without signs of early 
tumor progression, which had a mean time of 23.3  days 
(p = 0.685, Student’s t test), progression free survival was 
reduced from 320 to 185  days (HR 2.3; CI 95% 1.3–4.0; 
p = 0.0042, log-rank test) and overall survival from 778 to 
329 days (HR 2.9; CI 95% 1.6–5.1; p = 0.0005). A multi-
variate Cox regression analysis revealed that the Karnof-
sky performance score, O-6-methylguanine-DNA-methyl-
transferase (MGMT) promoter methylation, and signs of 
early tumor progression are prognostic markers of overall 
survival. Early tumor progression at the start of radiother-
apy is associated with a worse prognosis for glioblastoma 
patients. A standardized baseline MRI might allow for bet-
ter patient stratification.
Keywords Glioblastoma · MGMT promoter · Treatment 
delay · Magnetic resonance imaging · Survival
Introduction
Malignant gliomas are the most common brain tumor 
entity, and from those, glioblastoma is one of the most 
threatening. The current first-line treatment protocol 
includes surgery followed by combined radio- and chem-
otherapy [1]. Although this treatment protocol is very 
aggressive, the median survival time of 14 months reflects 
a poor prognosis. It is a common sentiment that an early 
treatment initiation is important for optimal tumor control. 
Nevertheless, reliable prospective data supporting this are 
lacking. Where one retrospective analysis indicated that 
delaying radiotherapy increased the risk of death by 9% 
weekly [2], others showed no evidence of an effect on over-
all survival [3, 4]. Today most oncologists would agree that 
Abstract Molecular markers define the diagnosis of glio-
blastoma in the new WHO classification of 2016, challeng-
ing neuro-oncology centers to provide timely treatment 
initiation. The aim of this study was to determine whether 
a time delay to treatment initiation was accompanied by 
signs of early tumor progression in an MRI before the start 
of radiotherapy, and, if so, whether this influences the sur-
vival of glioblastoma patients. Images from 61 patients 
with early post-surgery MRI and a second MRI just before 
the start of radiotherapy were examined retrospectively 
for signs of early tumor progression. Survival information 
was analyzed using the Kaplan–Meier method, and a Cox 
multivariate analysis was performed to identify independ-
ent variables for survival prediction. 59 percent of patients 
showed signs of early tumor progression after a mean time 
of 24.1 days from the early post-surgery MRI to the start of 
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delaying the initiation of radiotherapy for up to 4  weeks 
after tumor resection is not harmful [5, 6].
Given the dismal prognosis, new therapeutic concepts 
are needed urgently and require prospective evaluation 
within clinical trials. In the neuro-oncological field, ref-
erence histology and molecular marker evaluation with 
O-6-methylguanine-DNA-methyltransferase (MGMT) 
promoter methylation are now widely used for molecular 
analysis of glioblastoma for inclusion in clinical trials (e.g. 
Centric, Glarius). It is likely that up-and-coming markers 
such as the mutated isocitrate dehydrogenase, which is now 
an integral standard in the amended WHO classification 
[7], will also require more upfront testing time for patients 
in the future. This implies a potential critical delay in treat-
ment initiation that could endanger the treatment outcome, 
especially if the markers are evaluated centrally within a 
clinical trial [8].
We examined retrospectively the MRIs and clinical 
course of 61 glioblastoma patients in their first-line treat-
ment and addressed whether the MRI signs of early tumor 
progression, which occur during the waiting time to treat-
ment initiation, are prognostic of survival.
Materials and methods
Patient selection
We screened our database from the years 2009 to 2013 for 
patients with a histologically confirmed diagnosis of glio-
blastoma that had post-surgery MRI as well as a baseline 
MRI before start of radiotherapy. Patients were identified 
according to the inclusion criteria of having a well-docu-
mented clinical course and sufficient data for analysis, a 
post-surgery MRI, and a baseline MRI. As a substantial 
number of patients (22) was registered within clinical tri-
als, we excluded patients >75  years, with Karnofsky per-
formance status <70, or with surgical complications that 
would have interfered with a participation in a clinical trial, 
leaving a total of 61 patients for analysis.
Treatment regimens
Patients treated within clinical trials gave informed con-
sent and were treated according to the treatment plans. At 
the date of writing this manuscript, two of the three clini-
cal trials are already published as negative trials with no 
effect on overall survival, leaving a total of three patients 
that received an experimental chemotherapy of unpub-
lished activity. Patients within the clinical routine also gave 
informed consent for further scientific analysis of their 
clinical dataset and were treated according to the local 
guidelines with combined radio- and chemotherapy with 
Temozolomide [1]. The study design was approved by 
the local ethics committee under the registration number 
14-101-0035.
Imaging procedures
Initial diagnostic, intra-surgery or post-surgery, base-
line and follow-up MRIs were used for analysis accord-
ing to hospital guidelines. In brief, T1 contrast-enhanced 
sequences were used to localize the tumor and possible 
early recurrence by an experienced radiological special-
ist (CW) and a neuro-oncologist (MU). New T1 contrast-
enhancing lesions distant from the resection cavity, new 
nodular contrast-enhancing lesions at the border of the 
resection cavity and an increase in residual tumor were 
considered signs of early tumor progression.
Tumor progression and overall survival
Progression-free survival was defined as the time from sur-
gery to the first tumor recurrence after surgery. It was cen-
sored when death occurred before MRI detected progres-
sion or if lost to follow-up. Overall survival was defined 
as the time from initial surgery to death. If death did not 
occur at the time of data lockup in April 2016, events were 
marked as censored.
Statistical analysis
Gender, age, Karnofsky performance score (KPS), extent of 
resection, MGMT promoter methylation, waiting time and 
first-line and second-line therapy were registered retrospec-
tively using the original patient charts and trial documenta-
tion. Differences between the patient group for early tumor 
progression and the group with stable disease at baseline 
MRI were analyzed using the Fisher’s exact test for fre-
quency distributions, and, after testing for normal distribu-
tion, the t test or the Mann-Whitney-U-test, as appropriate. 
Progression-free and overall survival was analyzed using 
the Kaplan–Meier method. Differences between the two 
groups were analyzed for statistical significance by using 
the log-rank test. Age, KPS, extent of resection, MGMT 
promoter methylation and signs of early tumor progression 
were included in a multivariate Cox regression analysis 
for overall survival. Correlation between delay to baseline 
MRI and overall survival was analyzed using the Spear-
man’s ρ method. Receiver operating characteristic (ROC) 
analysis with Youden’s J statistic was used to discern the 
best cut-off time to detect signs of early tumor progression 
[9]. All statistical analyses were performed using SPSS and 
Graph Pad (JBK and IYE).
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Results
Signs of early tumor progression at baseline MRI
We analyzed our dataset of 61 patients with a 24 h post-sur-
gery and a baseline MRI just before initiation of radiother-
apy for signs of early tumor progression. 36 of 61 patients 
(59%) showed signs of early tumor progression. 9 of 36 
patients (25%) had a distant new lesion not directly associ-
ated with the original resection site, 27 of 36 patients (75%) 
showed a new lesion in the vicinity of the resection cav-
ity, and 28 of 36 patients (78%) had a progression of resid-
ual tumor (see Supplementary Fig. 1 for illustration). The 
mean waiting time in the group with signs of early tumor 
progression to baseline MRI was 24.1  days; in the group 
with no progress it was 23.3  days (p = 0.685; Student’s t 
test).
Patient characteristics
Before addressing a possible effect on survival we char-
acterized both groups with and without signs of early 
tumor progression for confounding variables. The groups 
were evenly distributed for gender, age, Karnofsky per-
formance scale (KPS), MGMT promoter methylation, 
delay to initiation of radiotherapy, participation in clini-
cal trials and bevacizumab use as outlined in Table  1. 
Concerning the extent of resection the group with early 
tumor progression had more biopsies (n = 12/36 (33%) 
vs. n = 1/25 (4%); p = 0.009; Fisher’s exact test) and 
had fewer patients receiving adjuvant chemotherapy 
(n = 24/36 (67%) vs. n = 23/25 (92%); p = 0.030; Fisher’s 
exact test) and second-line surgery (n = 5/35 (14%) vs. 
n = 11/25 (44%); p = 0.016; Fisher’s exact test).
Table 1  Patient characteristics 
of the two groups with and 
without signs of early tumor 
progression
KPS Karnofsky performance status, MGMT O6-methylguanine-DNA methyltransferase, adj. adjuvant, 
TMZ temozolomide, IQR interquartile range, SD standard deviation
Statistical analysis: age, extent of resection, experimental protocols, adj. chemotherapy, bevacizumab use, 
and second line therapy, Fisher’s exact test; age, and waiting time, t test; gender, and numbers of TMZ 
cycles, Man Whitney U test







 Female 19 (53%) 10 (40%) p = 0.435
 Age in years (SD) 56.3 (11, 4) 58.2 (9, 3) p = 0.503
 KPS (IQR) 80 (80–90) 80 (80–90) p = 0.671
Extent of resection
 Total 2 (6%) 4 (16%) p = 0.216
 Partial 22 (61%) 20 (80%) p = 0.163
 Biopsy only 12 (33%) 1 (4%) p = 0.009
MGMT promotor status
 Available 29 (81%) 19 (76%)
 Methylated 10 (35%) 4 (21%) p = 0.354
Waiting time to
 Baseline MRI in days (SD) 24.1 (7, 1) 23.3 (6, 6) p = 0.685
 Radiotherapy (SD) 29.9 (7, 5) 30.9 (6, 1) p = 0.607
Patients treated within experimental 
protocols
15 (42%) 7 (28%) p = 0.170
First line therapy
 Adj. chemotherapy 24 (67%) 23 (92%) p = 0.030
 Numbers of TMZ cycles (IQR) 4 (2–6) 6 (4–8) p = 0.143
 Bevacizumab use at any time 12 (33%) 7 (28%) p = 0.781
Second line therapy
 2nd surgery 5 (14%) 11 (44%) p = 0.016
 2nd radiotherapy 8 (22%) 8 (32%) p = 0.555
 2nd line chemotherapy 16 (44%) 14 (56%) p = 0.440
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Influence of early tumor progression on survival
We next asked the question whether the 36 of 61 patients 
that already showed a tumor recurrence at baseline MRI 
had a worse prognosis or not. The group with no signs of 
early tumor progression showed a median progression-free 
survival (PFS) of 320  days (Fig.  1a). Patients with early 
tumor progression had a median PFS of 185 days, translat-
ing into a hazard ratio of 2.3 (CI 95% 1.3–4.0; p = 0.0042; 
log-rank test). Similar results were found for overall sur-
vival (OS) in Fig. 1b. Patients with no signs of early tumor 
progression had a median OS of 778 days, whereas patients 
with early progression had a median of 329  days, with a 
hazard ratio of 2.9 (CI 95% 1.6–5.1; p = 0.0005; log-rank 
test). With respect to the localization of the early tumor 
progression, there was no difference in terms of PFS or OS 
for an early tumor progression in the vicinity of or distant 
from the resection cavity (data not shown).
Early tumor progression is an independent prognostic 
marker for overall survival
As the groups with and without signs of early tumor 
progression had an imbalance for prognostic markers 
like extent of resection [10] and adjuvant chemotherapy 
[1], we asked whether signs of early tumor progression 
is still an independent marker for survival outcome. We 
therefore conducted a multivariate Cox regression analy-
sis with age, KPS, extent of resection, MGMT promoter 
methylation and signs for early tumor progression as 
independent variables (Table 2). KPS (p = 0.005), MGMT 
promoter methylation (p < 0.0001) and early tumor pro-
gression (p = 0.001) were revealed to be significant mark-
ers. Age that had been limited by the inclusion criteria 
to <75  years was not significant (p = 0.182). Extent of 
resection defined by biopsy also showed no significance 
(p = 0.484) in our data set.
For patients with a documented early tumor 
progression at baseline MRI, the time delay 
to the initiation of radiotherapy correlates with overall 
survival
Given the assumption of a linear tumor growth and a 
stable detection limit defined by MRI technology, there 
should be a theoretical time point when tumor growth can 
be first detected. We therefore asked whether the presence 
of signs of tumor progression at an early baseline MRI 
compared to a late time point would be reflective of the 
tumor growth velocity and ultimately its prognosis. There 
was a significant correlation between the time to base-
line MRI and OS in the group with signs of early tumor 
progression (Fig.  2; p = 0.023 Spearman’s ρ), whereas 
for the patients without progression these factors did not 
Fig. 1  Influence of early tumor progression on survival. Panel a 
shows progression-free survival in days from surgery to first progres-
sion, and Panel b shows overall survival for patients showing signs 
of early tumor progression (early progression) or not (no progres-
sion) at baseline MRI. In a, the median was 185 and 320 days, HR 
2.3; CI 95% [1.3–4.0]; p = 0.0042, and in b, the median was 329 and 
776 days, HR 2.9; CI 95% [1.6–5.1]; p = 0.0005, log-rank test
Table 2  Multivariate Cox regression analysis for overall survival
KPS Karnofsky performance status, MGMT O6-methylguanine-DNA 
methyltransferase, OR odds ratio, CI confidence interval
Covariable OR 95% CI Significance
Age 0.962 0.908–1.018 p = 0.182
KPS 1.090 1.027–1.196 p = 0.005
Extent of resection (not 
biopsy)
1.512 0.476–4.804 p = 0.484
MGMT 16.946 3.687–77.898 p < 0.0001
Early tumor progression 0.182 0.066–0.502 p = 0.001
253J Neurooncol (2017) 132:249–254 
1 3
correlate. This suggests that patients with detected tumor 
growth in two consecutive MRIs in a short time window 
have a worse prognosis compared to patients for which 
the time window is extended. In contrast, if no early 
tumor progression was detected at baseline MRI, timing 
was irrelevant for prognosis.
Optimal time point for baseline MRI
Current clinical trials in neuro-oncology demand only in 
the cases of treatment delayed beyond 28 days an additional 
baseline MRI following the post-surgery MRI. Knowing 
the correlation between the time delay to baseline MRI and 
OS, we asked if there is an ideal time point to check for 
signs of early tumor progression. We therefore performed a 
ROC analysis, which was not significant. Cautiously inter-
preted, one might consider the Youden’s index of 0.236 as 
an indicator that 24  days are a cutoff point to determine 
signs of early tumor progression.
Discussion
The data presented analyzed the relevance of early tumor 
progression and contributed to the long debate on the ideal 
timing of adjuvant therapy in the treatment of glioblastoma 
patients. As outlined in the introduction, there are conflict-
ing reports in the literature. The latest report by Han et al. 
advocates a time window for treatment initiation [5]. Sur-
prisingly studies examining the prognostic value of time 
delay to treatment did not use imaging to search for signs of 
tumor progression.
Although this study is a retrospective analysis, to our 
knowledge it is the first report examining consecutive 
MRIs for prognostic signs before the initiation of radio-
therapy. There is a report of Stensjoen et al. that examined 
the growth dynamics of untreated glioblastomas before 
initial surgery [11]. This group reported a growth rate of 
1.4% per day and a volume doubling time of 50 days. They 
concluded that poor treatment logistics influence tumor 
size before surgery. Pennington et  al. examined MRIs 
between surgery and the initiation of radiotherapy, similar 
to our approach [12]. They observed a median time delay 
of 31.5  days between the scans and calculated a growth 
of 35%, comparable to the report by Stensjoen et  al. The 
conclusion was that given the growth kinetics, it is unlikely 
that tumor cells outgrew the usual 2–3 cm margin for radio-
therapy within the given timeframe. Both groups did not 
correlate growth kinetics with clinical outcome parameters 
like PFS and OS.
A correlation done by Gladwish et al. comparing post-
surgery and post-radiotherapy MRIs allowed a prognostic 
prediction, similar to our results [13]. The timing of the 
analyzed consecutive MRIs over radiotherapy raises the 
question of pseudo-progression or pseudo-responses and 
possibly clouds the predictive value of the MRIs. Add-
ing advanced MRI techniques including MRI perfusion 
and cerebral blood volume [14] or MRI spectroscopy [15] 
did not completely help in discriminating true progress 
from pseudo-progress in this time setting before and after 
radiotherapy.
An advantage of our study is that timing two MRIs 
before the initiation of radiotherapy excludes any thera-
peutic influence. We show that at the time radiotherapy 
is initiated at least 60% of patients already show signs of 
tumor recurrence, which comes with a poor prognosis, rais-
ing the question of whether to repeat surgery [16]. On the 
other hand, one can argue that early surgical re-resection 
will not correct the prognosis, and that early detection of 
tumor recurrence reflects the more aggressive nature of 
some glioblastomas. Unfortunately the 61 patients in our 
trial were not a sufficiently large cohort for an ROC analy-
sis determining an ideal time point to discriminate between 
the presence and absence of early tumor progression. More 
patients, ideally in a prospective trial with advanced MRI 
techniques or FET-PET, could address this.
Finally we have to raise questions concerning how clini-
cal studies into glioblastoma are currently conducted. Most 
protocols require an early (ideally within 24 h) post-surgery 
MRI and, only if a time delay exceeds 28 days to radiother-
apy, a baseline MRI (e.g. Centric, Director, Glarius). Given 
the additional information from our study we believe that 
all patients should have a baseline MRI as an independent 
prognostic marker for stratification. An additional theme 
to mention here is the time point of randomization. Some 
Fig. 2  Correlation between delay to baseline MRI and OS. The cor-
relation between the waiting time to baseline MRI and OS is shown. 
Only the group with signs of early tumor progression showed a sig-
nificant correlation between the time delay to baseline MRI and over-
all survival, with patients showing signs of early tumor progression 
at earlier time points having a worse prognosis. Spearman’s ρ test; 
p = 0.023
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trials randomize early at the initiation of radiotherapy (e.g. 
Centric, Glarius, Checkmate), while others randomize after 
the completion of radiotherapy (e.g. ACT IV, Novocure). 
Not surprisingly, these trials are hard to compare as the lat-
ter exclude patients that already show tumor recurrence. A 
mandatory baseline MRI, at a still-to-be-determined fixed 
time point before radiotherapy, would eliminate this and 
allow for comparison between early and late randomization 
trials.
In summary we show that 60% of glioblastoma patients 
in their first-line therapy experienced tumor progression as 
early as at the initiation of their radiotherapy. This recur-
rence is associated with a worse prognosis. We advocate 
for a standard baseline MRI to detect this unfavorable early 
course of disease both within and outside of clinical trials. 
The ideal time point of this MRI must be determined in 
further studies.
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